CTNM vs CVKD

Contineum Therapeutics, Inc. vs Cadrenal Therapeutics, Inc. — Valuation Comparison 2026

CTNM

Biotechnology
Contineum Therapeutics, Inc.
Quality
4.6
out of 10
Value Trap
12
SAFE
Price
$13.31
Last close
Models
7/13
Active
VS

CVKD

Biotechnology
Cadrenal Therapeutics, Inc.
Quality
4.7
out of 10
Value Trap
Price
$5.00
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType CTNM Fair ValueCTNM Upside CVKD Fair ValueCVKD Upside
Bayesian DCF Intrinsic $0.26 -98.2% $1.40 -72.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $3.43 -74.0% $1.16 -76.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CTNM vs CVKD — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CTNM vs CVKD — Which Stock Is More Undervalued?

CVKD scores higher with a 4.7/10 quality rating vs CTNM's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Contineum Therapeutics, Inc. (CTNM) and Cadrenal Therapeutics, Inc. (CVKD) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CTNM currently trades at $13.31 with a QOC of 4.6/10, while CVKD trades at $5.00 with a QOC of 4.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).